As AGAP requires a powerful carrier and protector, while ATF is in need of a carrier that facilitates cancer cell targeting and protects from enzymatic degradation and renal filtration, fuzing AGAP and ATF appeared to be effective method, to achieve the goal. Here, PLAU is linked to cancer.